ELITE PHARMACEUTICAL
ELI
ELI was delisted on the 20th of May, 2009.
3 hedge funds and large institutions have $28K invested in ELITE PHARMACEUTICAL in 2021 Q4 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.
211% more capital invested
Capital invested by funds: $9K → $28K (+$19K)
200% more funds holding
Funds holding: 1 → 3 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fisher Asset Management
Camas,
Washington
|
+$3K |
Top Sellers
ELI Hedge Fund Activity: Q4 2021 in Review
3 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in ELITE PHARMACEUTICAL (ELI) for Q4 2021, worth a combined $28K — up 211% from $9K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new ELI positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fisher Asset Management, opening a new position worth an estimated $3K.
- 3 institutional investors held ELITE PHARMACEUTICAL (ELI) as of Q4 2021, up from 1 in Q3 2021.
- Funds reported $28K of ELITE PHARMACEUTICAL stock for Q4 2021, up 211% quarter-over-quarter.
- 2 funds opened new ELITE PHARMACEUTICAL positions in Q4 2021 and 0 closed out, a net change of +2 holders.
- The largest ELITE PHARMACEUTICAL buyer in Q4 2021 was Fisher Asset Management, an estimated $3K added.
Based on aggregated 13F filings for Q4 2021.